keyword
MENU ▼
Read by QxMD icon Read
search

NSCLC surgery

keyword
https://www.readbyqxmd.com/read/29139039/genetic-screening-and-molecular-characterization-of-met-alterations-in-non-small-cell-lung-cancer
#1
M Saigi, A McLeer-Florin, E Pros, E Nadal, E Brambilla, M Sanchez-Cespedes
PURPOSE: Aberrant activation of MET as a result of exon 14-skipping (METex14) mutations or gene amplification is an oncogenic mechanism in non-small cell lung carcinoma (NSCLC) and a potential therapeutic target. The purpose of this study was to characterize MET alterations in a cohort of NSCLC patients treated with surgery. METHODS AND PATIENTS: 157 NSCLCs of various histopathologies, including pulmonary sarcomatoid carcinomas (PSC), were tested for MET alterations...
November 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29137276/potential-clinical-value-of-pet-ct-in-predicting-occult-nodal-metastasis-in-t1-t2n0m0-lung-cancer-patients-staged-by-pet-ct
#2
Xiang Zhou, Ruohua Chen, Gang Huang, Jianjun Liu
We assessed the clinical value of 2-fluoro-2-deoxyglucose ((18)F-FDG) PET/CT imaging for predicting occult nodal metastasis in non-small cell lung cancer (NSCLC) patients. This retrospective study included 54 patients with T1-2N0M0 NSCLC who had undergone (18)F-FDG PET/CT before surgery. Occult nodal metastasis was detected in 25.9% (14/54) of the patients. Immunohistochemical analysis revealed that increased glucose transporter 1 expression was associated with occult nodal metastasis, but hexokinase 2 expression was not...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29136212/neoadjuvant-and-adjuvant-therapy-for-stage-iii-non-small-cell-lung-cancer
#3
Shun-Ichi Watanabe, Kazuo Nakagawa, Kenji Suzuki, Kazuya Takamochi, Hiroyuki Ito, Jiro Okami, Keiju Aokage, Hisashi Saji, Hiroshige Yoshioka, Yoshitaka Zenke, Tadashi Aoki, Yasuhiro Tsutani, Morihito Okada
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local and microscopic systemic disease, because the 5-year survival of patients with Stage III NSCLC who underwent surgical resection alone has been dismal. One way to improve surgical outcome is the administration of chemotherapy before or after the surgical procedure. During the last two decades, many clinical studies have focused on developing optimal adjuvant or neoadjuvant chemotherapy regimens that can be combined with surgical treatment and/or radiotherapy...
November 9, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29129443/adjuvant-chemotherapy-with-or-without-bevacizumab-in-patients-with-resected-non-small-cell-lung-cancer-e1505-an-open-label-multicentre-randomised-phase-3-trial
#4
Heather A Wakelee, Suzanne E Dahlberg, Steven M Keller, William J Tester, David R Gandara, Stephen L Graziano, Alex A Adjei, Natasha B Leighl, Seena C Aisner, Jan M Rothman, Jyoti D Patel, Mark D Sborov, Sean R McDermott, Roman Perez-Soler, Anne M Traynor, Charles Butts, Tracey Evans, Atif Shafqat, Andrew E Chapman, Samer S Kasbari, Leora Horn, Suresh S Ramalingam, Joan H Schiller
BACKGROUND: Adjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC. METHODS: We did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC...
November 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29125868/local-thoracic-therapy-improve-prognosis-for-stage-iv-non-small-cell-lung-cancer-patients-combined-with-chemotherapy-a-surveillance-epidemiology-and-end-results-database-analysis
#5
Kaitai Liu, Dawei Zheng, GuoDong Xu, Zhennan Du, Shibo Wu
Patients with stage IV non-small cell lung cancer (NSCLC) comprise a heterogeneous group, and the optimal treatment for this group of patients is complex and debatable. We aimed to assess the effect of local thoracic therapy combined with chemotherapy on cancer specific survival (CSS). To evaluate the CSS of four subgroups of patients with stage IV NSCLC according to four different treatment modalities: combined modality of Chemotherapy, Surgery, and Radiation (Chem+Sur+RT), Chemotherapy and Radiation (Chem+RT), Chemotherapy and Surgery (Chem+Sur), and Chemotherapy only (Chem Only) by analyzing the Surveillance, Epidemiology, and End Results (SEER)-registered database...
2017: PloS One
https://www.readbyqxmd.com/read/29124025/efficacy-of-single-port-video-assisted-thoracoscopic-surgery-lobectomy-compared-with-triple-port-vats-by-propensity-score-matching
#6
Kyung Sub Song, Chang Kwon Park, Jae Bum Kim
Background: In recent years, single-port video-assisted thoracoscopic surgery (VATS) for lobectomy in non-small cell lung cancer (NSCLC) patients has become increasingly common. The objective of this study was to compare the feasibility and safety of single-port and triple-port VATS lobectomy. Methods: A total of 73 patients with NSCLC who underwent VATS lobectomy from December 2011 to August 2016 were retrospectively reviewed, including 47 in the triple-port group and 26 in the single-port group...
October 2017: Korean Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29121474/outcomes-following-video-assisted-thoracoscopic-lobectomy-versus-open-lobectomy-for-early-stage-lung-cancer-in-older-adults
#7
Nicole Ezer, Minal Kale, Keith Sigel, Sameer Lakha, Grace Mhango, Emily Goodman, Daniel Nicastri, Scott Swanson, Alfred Neugut, Juan P Wisnivesky
RATIONALE: Video-assisted thoracoscopic surgery and open lobectomy are both standard of care for treatment of early stage NSCLC because of equivalent long-term survival. OBJECTIVE: To evaluated whether the improved peri-operative outcomes associated with VATS are explained by differences in case volume and specialty training. METHODS: We analyzed the Surveillance, Epidemiology and End Results-Medicare linked registry to identify stage I-II NSCLC in patients above 65 years of age...
November 9, 2017: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/29119942/18f-faza-pet-ct-in-the-preoperative-evaluation-of-nsclc-comparison-with-18f-fdg-and-immunohistochemistry
#8
Paola Mapelli, Valentino Bettinardi, Federico Fallanca, Elena Incerti, Antonia Compierchio, Francesca Rossetti, Angela Coliva, Annarita Savi, Claudio Doglioni, Giampiero Negri, Luigi Gianolli, Maria Picchio
PURPOSE: To assess the capability of 18F-FAZA PET/CT in identifying intratumoral hypoxic areas in early and locally advanced non-small cell lung cancer (NSCLC) patients and to compare 18F-FAZA PET/CT with 18F-FDG PET/CT and histopathological biomarkers and to investigate whether the assessment of tumour to blood (T/B) and tumour to muscle (T/M) ratios provides comparable information regarding the hypoxic fractions of the tumour. MATERIALS AND METHODS: Seven patients with NSCLC were prospectively enrolled (3 men, 4 women; median age: 71 years; range 63-80)...
November 8, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/29116951/induction-therapies-plus-surgery-versus-exclusive-radiochemotherapy-in-stage-iiia-n2-non-small-cell-lung-cancer-nsclc
#9
Branislav Jeremić
In spite of the growing body of data from prospective randomized clinical trials (PRCTs) and meta-analyses, the optimal treatment approach in patients with stage IIIA non-small cell lung cancer remains unknown. This review focuses on the available data directly confronting induction chemotherapy or induction radiochemotherapy (RT-CHT) when followed by surgery with exclusive RT-CHT. Seven PRCTs and 4 meta-analyses investigated this issue. In addition, numerous retrospective studies attempted to identify potential predictors and/or prognosticators that may have influenced the decision to offer surgery in a particular patient subgroup...
November 7, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29114590/oncological-outcomes-from-trimodality-therapy-receiving-definitive-doses-of-neoadjuvant-chemoradiation-%C3%A2-60%C3%A2-gy-and-factors-influencing-consideration-for-surgery-in-stage-iii-non-small-cell-lung-cancer
#10
Melissa A L Vyfhuis, Neha Bhooshan, Whitney M Burrows, Michelle Turner, Mohan Suntharalingam, James Donahue, Elizabeth M Nichols, Josephine Feliciano, Søren M Bentzen, Shahed Badiyan, Shamus R Carr, Joseph Friedberg, Charles B Simone, Martin J Edelman, Steven J Feigenberg, Pranshu Mohindra
Purpose: Guidelines for locally advanced non-small cell lung cancer (LA-NSCLC) recommend definitive chemoradiation therapy (CRT) for cN2-N3 disease, reserving surgery for patients with minimal nodal involvement at presentation. The current literature suggests that surgery after CRT for stage III NSCLC can improve freedom-from-recurrence (FFR) but has not consistently demonstrated an improvement in overall survival, perhaps partly due to the low (45-50.4 Gy) preoperative doses delivered that result in low rates of mediastinal nodal clearance...
July 2017: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/29114469/update-on-large-cell-neuroendocrine-carcinoma
#11
REVIEW
Kenzo Hiroshima, Mari Mino-Kenudson
High-grade neuroendocrine carcinomas of the lung are classified into two categories: large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). While typical cases of LCNEC are morphologically distinct from SCLC, the differentiation between LCNEC and SCLC can be challenging in some cases. In fact, there are borderline high-grade neuroendocrine carcinomas that morphologically fall between LCNEC and SCLC. Growing evidence suggests that LCNEC is a histologically and biologically heterogeneous group of tumors...
October 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29110950/validity-of-the-updated-european-society-of-thoracic-surgeons-staging-guideline-in-lung-cancer-patients
#12
Akif Turna, Hüseyin Melek, H Volkan Kara, Burcu Kılıç, Ezel Erşen, Kamil Kaynak
OBJECTIVE: The European Society of Thoracic Surgeons (ESTS) has proposed a revised preoperative lymph node staging guideline for patients with potentially resectable non-small cell lung cancer (NSCLC). We aimed to assess the validity of this revised ESTS guideline and survival results in our patient cohort. METHODS: A total of 571 patients with potentially resectable NSCLC seen between January 2004 and November 2013 were included in the study. The preoperative mediastinal staging was performed by video-assisted cervical mediastinoscopy or video-assisted mediastinoscopic lymphadenectomy in all patients except those with peripheral cT1N0 nonadenocarcinoma tumors...
September 27, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29110716/postoperative-survival-of-egfr-tki-targeted-therapy-in-non-small-cell-lung-cancer-patients-with-egfr-19-or-21-mutations-a-retrospective-study
#13
Wenjing Yang, Yibo Gao, Xuelian Li, Jing Zhang, Tiejun Liu, Xiaoli Feng, Hao Pan, Xiaofan Yang, Shuanghua Xie, Xiaoshuang Feng, Zhangyan Lv, Yonggang Wang, Zhaoli Chen, Jie He
BACKGROUND: The aim of this retrospective study is to identify epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer patients and to compare the long-term postoperative outcomes in different EGFR-TKI-targeted therapy effects between the different EGFR mutation groups. METHODS: A total of 2094 postoperative non-small cell lung cancer (NSCLC) patients with EGFR gene detection were collected in the Department of Pathology in the Cancer Hospital Chinese Academy of Medical Sciences from January 2003 to January 2014...
November 6, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29109628/intraoperative-use-of-dexmedetomidine-is-associated-with-decreased-overall-survival-after-lung-cancer-surgery
#14
Juan P Cata, Vinny Singh, Brenda M Lee, John Villarreal, John R Mehran, J Yu, Vijaya Gottumukkala, Hagar Lavon, Shamgar Ben-Eliyahu
Background and Aims: The aim is to evaluate the association between the use of intraoperative dexmedetomidine with an increase in recurrence-free survival (RFS) and overall survival (OS) after nonsmall cell lung cancer (NSCLC) surgery. Material and Methods: This was a propensity score-matched (PSM) retrospective study. Single academic center. The study comprised patients with Stage I through IIIa NSCLC. Patients were excluded if they were younger than 18 years. Primary outcomes of the study were RFS and OS...
July 2017: Journal of Anaesthesiology, Clinical Pharmacology
https://www.readbyqxmd.com/read/29106887/patterns-of-treatment-and-outcomes-for-definitive-therapy-of-early-stage-non-small-cell-lung-cancer
#15
Nirav S Kapadia, Luca F Valle, Julie A George, Reshma Jagsi, Thomas A D'Amico, Elisabeth U Dexter, Fawn D Vigneau, Feng Ming Kong
BACKGROUND: Definitive surgical and radiation therapy (RT) treatments are evolving rapidly for stage I non-small cell lung cancer (NSCLC). We hypothesized that utilization of definitive therapies increased between 2000 and 2010 and that survival improved for stage I NSCLC patients over the same time period. Secondary objectives were determining trends in patterns of care and predictors of utilization. METHODS: Population-based, observational, comparative effectiveness study used Surveillance, Epidemiology, and End Results-18 data from 2000 to 2010...
October 17, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29105365/platelet-to-lymphocyte-ratio-predicts-the-prognosis-of-patients-with-non-small-cell-lung-cancer-treated-with-surgery-and-postoperative-adjuvant-chemotherapy
#16
Michihito Toda, Takuma Tsukioka, Nobuhiro Izumi, Hiroaki Komatsu, Satoshi Okada, Kantaro Hara, Hikaru Miyamoto, Ryuichi Ito, Toshihiko Shibata, Noritoshi Nishiyama
BACKGROUND: Markers of preoperative tumor immunity, such as platelet-to-lymphocyte ratio (PLR), have been reported to be prognostic factors for patients with various cancers. However, the relationship between PLR and the prognosis of non-small cell lung cancer (NSCLC) patients treated with surgery and adjuvant chemotherapy as a multidisciplinary treatment is unknown. METHODS: We enrolled 327 NSCLC patients treated surgically with or without adjuvant chemotherapy (78 and 249 patients, respectively) at our hospital from 2008 to 2012...
November 3, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/29103238/neo-adjuvant-chemo-radiation-to-60-gray-followed-by-surgery-for-locally-advanced-non-small-cell-lung-cancer-patients-evaluation-of-trimodality-strategy
#17
Sarit Appel, Jeffry Goldstein, Marina Perelman, Tatiana Rabin, Damien Urban, Amir Onn, Tiberiu R Shulimzon, Ilana Weiss, Sivan Lieberman, Edith M Marom, Nir Golan, David Simansky, Alon Ben-Nun, Yaacov Richard Lawrence, Jair Bar, Zvi Symon
BACKGROUND: Neoadjuvant chemo-radiation therapy (CRT) dosages in locally advanced non-small cell lung cancer (NSCLC) were traditionally limited to 45 Gray (Gy). OBJECTIVES: To retrospectively analyze outcomes of patients treated with 60 Gy CRT followed by surgery. METHODS: A retrospective chart review identified patients selected for CRT to 60 Gy followed by surgery between August 2012 and April 2016. Selection for surgery was based on the extent of disease, cardiopulmonary function, and response to treatment...
October 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/29097801/efhd2-promotes-epithelial-to-mesenchymal-transition-and-correlates-with-postsurgical-recurrence-of-stage-i-lung-adenocarcinoma
#18
Chi-Chen Fan, Wei-Chung Cheng, Yu-Chuen Huang, Yuh-Pyng Sher, Nia-Jhen Liou, Yu-Chuan Chien, Pei-Shan Lin, Pei-Syuan Lin, Chung-Hsuan Chen, Wei-Chao Chang
Surgery is the only curative treatment for early-stage non-small cell lung cancer (NSCLC) patients. However, approximately one-third of these patients develop recurrence, which remains the main cause of mortality in the postsurgical treatment of NSCLC. Many molecular markers have been proposed to predict recurrence of early-stage disease, but no marker has demonstrated sufficient reliability for clinical application. In the present study, the novel protein EF-hand domain-containing protein D2 (EFHD2) was identified as expressed in highly metastatic tumor cells...
November 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29081843/clinical-staging-of-nsclc-current-evidence-and-implications-for-adjuvant-chemotherapy
#19
REVIEW
David J Heineman, Johannes M Daniels, Wilhelmina H Schreurs
Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival of 18%. Staging NSCLC patients is crucial because it determines the choice of treatment and prognosis. Clinical staging is a complex process that comes with many challenges and with low accuracy between the clinical and pathological stage. Treatment modalities for stage I-III NSCLC consist of surgical resection, radiotherapy and chemotherapy. This review describes the current evidence on staging and the implications on adjuvant chemotherapy...
September 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29078690/single-port-video-assisted-thoracoscopic-surgery-vats-right-pneumonectomy-a-case-report
#20
Matic Domjan, Ana Mavko, Tomaž Štupnik
When it comes to surgical treatment of non-small cell lung cancer (NSCLC), modern principles dictate that every possible effort should be made to avoid pneumonectomy, its debilitating consequences and a higher rate of complications. In marginal cases where video-assisted thoracoscopic surgery (VATS) sleeve or double sleeve lobectomy cannot be performed a conversion to open sleeve lobectomy is always preferred over a VATS pneumonectomy. We present a case of a 64-year-old male patient with two synchronous tumors of the right lung, both centrally located in the right upper and the right lower lobe...
2017: J Vis Surg
keyword
keyword
22646
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"